Introduction
Autoimmune epilepsies are a heterogeneous group of recently described refractory epilepsies. They have been characterized by a variety of clinical, serological and radiological features. A range of anti-neuronal antibodies, which are usually found in limbic encephalitis, including antibodies to GAD, [1] [2] [3] [4] VGKC-complex antibodies, [5] [6] [7] [8] [9] [10] [11] NMDA-R, [12] [13] [14] amongst others, have been associated with some of these disorders. Other, antibody negative epilepsy patients had radiological features of central nervous system inflammation, inflammatory infiltrates histologically or high CSF white cell counts and oligoclonal bands. 11 Immune therapy, including steroids and IVIg, has been used in these cases and resulted in clinical improvement. Best outcomes were associated with a short duration of the underlying illness. 5, 12 Long-term immune therapy has often been utilized in these cases. In this article, we describe a small cohort of patients who had a rapid, sustained response to a short course of IVIg, despite limited serological and radiological evidence for an underlying autoimmune process. This response was independent of the varying seizure phenotypes. Interestingly, all 3 patients shared a certain EEG pattern.
Case 1
A 17 year old right handed girl, with a diagnosis of juvenile myoclonic epilepsy, was transferred in super-refractory status epilepticus of 3 days duration. Seizure semiology comprised ongoing episodes of alternating left and right sided facial jerking, eye deviation to the right, unresponsiveness and audible shallow breaths. These focal episodes frequently evolved to generalized tonic-clonic seizures. Despite escalating treatment in an ICU setting with intubation and anaesthetic agents, using high doses of LTG, LEV, TPM, VPA, PHT, clobazam, midazolam, magnesium and propofol infusions, she had ongoing seizures after 11 days.
EEG showed alternating left and right hemispheric epileptiform discharges with simultaneous contralateral frontal spike wave activity (Fig. 1a) .
Because of the hemispheric emphasis of the epileptiform discharges, reminiscent of Rasmussen's encephalitis, a treatment attempt with IVIg, at a dose of 0.4 g/kg/day for 5 days, was undertaken. Twelve hours after the first dose of IVIg, the seizures had terminated clinically, but she remained confused and drowsy. An EEG at this stage showed generalized slowing (Fig. 1b ). An MRI performed at this point was normal. By Day 15, the patient had made a full recovery and was sitting in bed doing her homework. Her EEG had completely normalized (Fig. 1c) . Anti-thyroid antibodies (serum collected prior to initiation of IVIG) returned as mildly positive (Table 1) .
She was discharged a week later and followed up in the clinic at 1, 3, 6 and 15 months. Repeat MRI head and EEG at 3 months post discharge were normal. No further IVIg has been administered. Her current AED regimen has been reduced to monotherapy with LTG 100 mg BD. No further seizures have been reported by the patient or her family.
Prior to this episode, she was thought to have a generalized epilepsy syndrome on the basis of a positive family history (the parents are first cousins and there is a history of epilepsy in the maternal grandmother), a history of absences and upper limb myoclonus and a routine interictal EEG showing a burst of 4 Hz generalized spike and polyspike and wave activity.
She had a past history of three admissions, at the ages of 6 months, 9 months and 2 years, to intensive care units with refractory status epilepticus (including one episode of epilepsia partialis continua aged 2 years old). Each episode lasted between 2 and 15 days. Ictal EEGs were reported to show continuous 4-5 Hz spike and polyspike and wave activity, which on various admissions occurred either independently over both hemispheres or unilaterally over either the right or left hemisphere. Treatment was reported to have been difficult and required midazolam infusions, nitrazepam, paraldehyde, PB, PHT and ACTH in various combinations.
Maintenance therapy initially consisted of VGB and PHT with poor control. Later, after addition of LTG, the patient became seizure-free for 5 years on monotherapy. Whilst mild development delay in speech was detected at 14 months of age, she was an average student and had aspirations of becoming a teacher.
Over the years, she had multiple negative investigations for underlying causes of the epileptic syndrome, including multiple genetic, immunological and metabolic tests (Table 1 ).
Case 2
A 69 year old female with a history of bipolar affective disorder (currently untreated) and ischaemic heart disease presented to our hospital in focal status epilepticus. There was no previous history of epilepsy. She had a two day history of confusion, epilepsia partialis continua comprising left-sided jerking movements involving her head, shoulder, arm, abdominal muscles and leg with occasional brief generalized tonic-clonic seizures. She had transient hyponatremia (120 mmol/l) in keeping with SIADH; other investigations, including a range of neuroimaging and serological studies and screens for malignancy was normal (Table 1) . Consent for a lumbar puncture was not given.
In spite of treatment with high-dose PHT, DZP, LEV, VPA and TPM she had ongoing seizures for 48 h. An EEG showed right hemispheric rhythmic spike and spike wave activity, with very infrequent left frontal sharp waves (Fig. 2a) .
IVIg at a dose of 0.4 g/kg/day for 5 days was started. 12-15 h after the first dose there was complete resolution of the clinical events. By day 2 (post second dose) her confusion resolved and the EEG changes had normalized (Fig. 2b) . Despite stopping of all AEDs against medical advice and with no further administration of IVIg, she continues to be seizure free at 12 months.
Case 3
A 42 year old male, was admitted with multiple seizures. He had a past history of encephalitis at the age of three and developed recurrent seizures at the age of nine. These seizures were refractory focal seizures with dyscognition, comprising an aura of a rising epigastric sensation followed by vocalization and evolution to generalized tonic clonic activity and post-ictal aggression. These occurred approximately two to three times a week. He also reported frequent isolated auras. At age 22, he underwent evaluation for epilepsy surgery. Scalp EEG recordings revealed occasional left hemispheric discharges, with an emphasis over the fronto-temporal region. His epilepsy was refractory to PHT, CBZ, OxC, LTG, LEV, PB, and clobazam.
In 1992, he underwent intracranial EEG recording and finally proceeded to left anterior amygdalohippocampectomy. Histological examination revealed gliosis, without any evidence of inflammation or malignancy. Surgery resulted in seizure freedom for 9 months. Later, seizure frequency drastically increased with numerous auras per day, second-daily focal seizures and weekly secondarily generalized tonic-clonic seizures. He was maintained on LEV and LTG and did not attend follow up appointments.
He was admitted to hospital after trauma, but was noted to have multiple seizures with post-ictal aggression. As his EEG showed similarities with the previously described cases -frequent unihemispheric epileptiform discharges with contralateral frontal spikes (Fig. 3a) -a treatment trial with IVIg at a dose of 0.4 g/kg for 5 days was commenced, without any other alteration in his AED regime. With this, his EEG remained unchanged. However, by day 2 he had no further seizures and remained completely seizure free for 4 months. He subsequently represented with 2 further seizures and was successfully treated again with 5 days of IVIg and monthly maintenance therapy. Currently, he experiences mild focal seizures with dyscognition, approximately once every 3 months, which represents a significant decrease in seizure frequency and cessation of tonic-clonic seizures. Of note, his EEG significantly improved after 6 months of treatment, with infrequent epileptiform discharges, detected only by prolonged EEG monitoring (Fig. 3b) . CSF showed a lymphocytic pleocytosis of 64 cells/mcl. Oligoclonal bands were not detected. Immunofluorescence studies of the patient's serum on mouse brain revealed a cytoplasmic staining pattern of cerebellar Purkinje cells, but no target antigen was identifiable on Immunoblot (Euroimmun); its pathophysiological significance is unclear. MRI brain showed only old left temporal post-surgical changes. Testing for other anti-neuronal antibodies (VGKC-complex, NMDA-R) were negative (Table 1) .
Discussion
IVIg has been investigated for refractory epilepsy in the past in a number of small studies and case series with variable effect. 15 The EFNS guidelines have recommended IVIg use in the setting of specific syndromes (RE, West syndrome, Landau-Kleffner syndrome). 16 In recent years, a heterogeneous group of immune mediated epilepsies has been described, based on the presence of a number of anti-neuronal antibodies (VKGC-complex, NMDA-R, GAD, etc.), inflammatory changes in CSF and neuroimaging. 1, 2, 5, 11, 17, 18 A subgroup of these patients responded to IVIg. Furthermore, IVIg has found new favour in the setting of superrefractory status epilepticus. However, it appears to be utilized when conventional treatment with AEDs has been exhausted and in the absence of markers of underlying autoimmunity. 19 A recent Cochrane review has found no clear evidence for efficacy of IVIg as a treatment for refractory epilepsy. 20 This paper describes a case series of patients with refractory epilepsy, who, whilst presenting heterogeneously in terms of clinical features and seizure types, had all a quick and sustained response to IVIg. Common to all 3 cases was a certain EEG pattern, namely unihemispheric epileptic discharges with contralateral frontal involvement, but without clear focal features. Based on this EEG pattern combined with the scenario of AED refractory seizures, a treatment trial with IVIg was commenced.
Even though none of our cases has RE, this EEG pattern draws parallels to it. RE is a hemispheric encephalitis which is widely believed to have an autoimmune basis. Progression is slowed with immunomodulatory treatment. 21, 22 The EEG in RE evolves over time, initially comprising lateralized epileptiform discharges from the affected hemisphere, and progressing to multifocal contralateral epileptiform discharges later in the disease course -termed ''false lateralisation''. 23, 24 Other syndromes sharing this pattern include Sturge-Weber, focal cortical dysplasia, hemiconvulsionhemiplegia-epilepsy-syndrome and PCDH19 related epilepsies. None of these fit our cases. None of our cases have a previous personal or family history of autoimmunity or cognitive impairment. Indeed, Case 3 is the only case in this series with strong clinical evidence of an autoimmune process (CSF pleocytosis, anti-neuronal antibodies). The progression of the EEG over time, in this case, is worth noting. Initially, pre-operative monitoring reported a predominantly focal area over the left fronto-temporal region, however, with infrequent left hemisphere discharges. Years later, on presentation to our service, sustained left hemisphere, epileptiform discharges, with contralateral frontal discharges were seen. With clinical improvement came a marked improvement in the EEG with infrequent epileptiform discharges, captured only during prolonged EEG telemetry. The progression of this EEG is similar to the changes seen in RE.
Case 1 represents the first reported case of a genetic generalized epilepsy with a probable immune component manifesting as super-refractory status epilepticus, responding to IVIg. Although some studies have alluded to a possible link between GGE and autoimmunity, 2, 25 it is often in the context of other autoimmune disorders and not in isolated GGE. Interestingly, the patient maintained the spike-wave hallmarks of genetic generalized epilepsy, but with the pattern described in this article. In contrast to previously reported cases of autoimmune epilepsies, the decision to treat with IVIg depended predominantly upon this EEG pattern, rather than more classical markers of CNS autoimmunity (anti-neuronal antibodies, CSF inflammatory markers, neuro-imaging).The quick and sustained response of IVIg in our patients is remarkable. Multiple mechanisms of IVIg, including immediate and long-lasting effects have been proposed. These included inhibition of inflammatory cytokines and neutralization of pathogenic antibodies, as well as long-term inactivation and apoptosis of both autoreactive T and B cells. [26] [27] [28] A similar rapid and sustained response to IVIg can also be seen in ITP and NMDA-R encephalitis. In ITP, this is mediated by enhancement of suppressor T lymphocyte function and a decrease in autoantibody production. 29, 30 Whilst the evidence for an autoimmune process in our cases is poor, this might would be a possible explanation for the ongoing remission in 2 of our 3 cases without further treatment with IVIg.Another mechanism that may have contributed to seizure freedom in our cases is the ability of IVIg to decrease permeability of the blood-brain barrier. This is an important function in refractory status epilepticus, where influx of pro-convulsive albumin into the CNS parenchyma occurs. 31 IVIg also prevents entry of immune cells and antibodies into the CNS, by blocking extracellular matrix proteins.
26-28
Although we contemplated the addition of steroids, the use of IVIg monotherapy led to a rapid, impressive clinical response in these cases. Although we cannot be sure if steroids would have worked, the literature does suggest that steroids as monotherapy appear less effective in autoimmune encephalitides, 12 possibly due to the broader mechanism of action of IVIg. In the third patient, IVIg was used immediately because of pattern recognition of the EEG and our previous experiences. In summary, we describe 3 cases with a characteristic, but nonspecific EEG pattern, which responded to treatment with IVIg. We wonder whether this EEG pattern has been seen in other cases of immune responsive epilepsy. If these EEG findings can be reproduced in larger studies, this could have significant clinical implications, most notable in the setting of refractory status epilepticus.
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